Background technology
The position that fungal infectious disease is invaded human body according to fungus is divided into 4 classes: superficial fungi disease, dermatomycosis, subcutaneous mycosis and systemic mycoses; The former two is collectively referred to as superficial mycosis, and the latter two are called again deep mycosis.Fungal infectious disease is divided into following several according to fungal infection difference: candida albicans bacterium infectious disease, Candida parapsilosis bacterium infectious disease, Candida glabrata infectious disease, infection by Cryptococcus neoformans disease, Gypsum Fibrosum shape sporidiole bacteria infectious disease, trichophyton infectious disease, aspergillus fumigatus infection disease.
In recent years, along with the extensive use of broad ectrum antibiotic, corticosteroid and immunosuppressant, advanced Clinics is as the popularization of organ transplantation etc., AIDS's is popular, and the impact of tumor Radiotherapy chemotherapy, cause fungal infection particularly deep fungal infection significantly rise, deep fungal infection has now become the major disease such as acquired immune deficiency syndrome (AIDS) and tumor main causes of death.
Reported at present and clinically conventional nitrogen azole compounds have ketoconazole (Ketoconazole, KCZ), fluconazol (Fluconazole, FCZ), voriconazole (Voriconazole, VCZ), itraconazole (Itraconazole, ICZ), amphotericin B (Amphotericin B, AMB) etc., but these compounds still exist, and above-mentioned toxic and side effects is large, narrow antimicrobial spectrum, easily produce the defects such as drug resistance, for example bring into play the required dosage of drug effect larger, thereby can produce larger toxic and side effects to human body.。
Summary of the invention
The object of the invention is, for deficiency of the prior art, provides a kind of application of medicine.
For achieving the above object, the technical scheme that the present invention takes is:
Throat azoles miazines compound is in an application of preparing in candida albicans bacterium infectious disease medicament, and described throat azoles miazines compound is N3-(4-fluorophenyl)-1H-pyrazolo [3,4-D] pyrimidine-3,4-diamidogen.
The invention has the advantages that: compound of the present invention has good antifungal activity to various superficial parts and deep fungal, compared with the antifungal drug of existing clinical practice, to there is the advantages such as efficient, hypotoxicity, anti-fungus spectra be wide, can be used for preparing antifungal drug.
Detailed description of the invention
Below detailed description of the invention provided by the invention is elaborated.
Embodiment 1
Below detailed description of the invention provided by the invention is elaborated.
(1) experimental technique: adopt conventional In Vitro Bacteriostasis experimental technique (to refer to: Antimicrob Agents Chemother 1995,39 (5): 1169)
1. materials and methods
(1) testing compound of the present invention: N3-(4-fluorophenyl)-1H-pyrazolo [3,4-D] pyrimidine-3,4-diamidogen
The experiment of particular compound:
Buy the Tocris Bioscience(U.S., Ellisville) ready-made compound (Cat. No. 2731) carries out cytologic experiment, and specifying information is as follows:
CGP57380,CAS?number:522629-08-9
Molecular weight: 244.23
Chemical name: N3-(4-fluorophenyl)-1H-pyrazolo [3,4-D] pyrimidine-3,4-diamidogen (N3-(4-Fluorophenyl)-1H-pyrazolo-[3,4-d] pyrimidine-3,4-diamine)
Molecular formula: C
11h
9fN
6.
Experimental strain is as follows:
This experiment has selected following 8 kinds of common human body cause illness's standard fungal bacterial strains as screening object:
Table 1 antifungal activity in-vitro screening strain subject
Strain name
|
Species
|
Strain number
|
Candida albicans bacterium |
Candida albicans
|
Y0109 |
Candida albicans bacterium |
Candida albicans
|
SC5314 |
Candida parapsilosis bacterium |
Candida parapsilosis
|
ATCC 22019 |
Candida glabrata |
Candida glabrata
|
537 |
Neogenesis cryptococcus |
cryptococcus neoformans
|
32609 |
Gypsum Fibrosum shape sporidiole bacteria |
Microsporum gypseum
|
Cmccfmza |
Trichophyton |
Trichophyton rubrum
|
Cmccftla |
Aspergillus fumigatus |
Aspergillus fumigatus
|
07544 |
(2) test method
Bacteria suspension preparation: above-mentioned fungus is cultivated 16 hours through 35 DEG C of YEPD fluid mediums, twice activation, with blood cell counting plate counting, adjusts bacteria concentration to 1 × 10 with RPM1640 fluid medium
4~1 × 10
5individual/mL.
Medicinal liquid preparation: get testing compound of the present invention and be dissolved in dimethyl sulfoxine, be made into the medicine storage liquid of 8.0mg/mL, be diluted to 640 μ g/mL with RPM1640 before experiment.
Inoculation: get drug sensitive plate, add RPMI RPMI-1640 200 μ l in No. 1 hole of every row, make blank; No. 12 hole adds bacterium liquid 200 μ l to be measured, makes negative control; 2 ~ No. 11 holes of the every row of drug sensitive plate add respectively bacterium liquid 180 μ l, fully mix, and make the final drug level in each hole be respectively 64,32,16,8,4,2,1,0.5,0.25 and 0.125 μ g/ml, and in each hole, DMSO content is all lower than 1%; Positive control, not containing medicine, is made in No. 12 holes.Control drug is fluconazol (FCZ), itraconazole (ICZ), voriconazole (VCZ), ketoconazole (KCZ), terbinafine (TBR), amphotericin B (AMB).
Cultivate and detect: establishing positive control hole optical density value (OD value) is 100%, taking optical density value than positive control hole lower than 80% lowest concentration of drug as minimal inhibitory concentration value (MIC
80).
(2) experimental result
In Vitro Bacteriostasis experimental result is in table 2.
Table 2 the compounds of this invention is to common pathomycete external activity (MIC, μ g/ml)
Compound |
Y0109 |
SC5314 |
Nearly flat 22019 |
New hidden 32609 |
Smooth 537 |
Cigarette song 07544 |
Red hair Cmccftla |
The little Cmccfmza of stone |
c1 |
8 |
8 |
2 |
1 |
1 |
>64 |
>64 |
>64 |
ICZ |
8 |
4 |
8 |
4 |
8 |
8 |
2 |
2 |
TRB |
64 |
32 |
1 |
1 |
4 |
0.5 |
0.125 |
0.0625 |
KCZ |
0.25 |
0.25 |
0.5 |
0.125 |
0.5 |
8 |
1 |
1 |
VCZ |
0.03125 |
0.0625 |
0.03125 |
0.0156 |
0.03125 |
0.25 |
0.03125 |
0.125 |
AMB |
2 |
1 |
2 |
1 |
2 |
2 |
1 |
0.125 |
FCZ |
0.5 |
0.5 |
1 |
1 |
1 |
>64 |
8 |
8 |
Note: KCZ. ketoconazole, FCZ. fluconazol, VCZ. Wo Likang azoles, ICZ. itraconazole, TRB. terbinafine, AMB amphotericin
Above-mentioned experimental result shows that compound of the present invention has good antifungal activity, and compound is all far better than fluconazol to the vitro inhibition activity of selected fungus, illustrates that the compounds of this invention can be used for preparing the medicine of anti-fungal infection.
The above is only the preferred embodiment of the present invention; it should be pointed out that for those skilled in the art, do not departing under the prerequisite of the inventive method; can also make some improvement and supplement, these improvement and the supplementary protection scope of the present invention that also should be considered as.